Menu

Image of the Day: Fountain of Youth

Neural plasticity wanes with age, but increasing the protein Arc—abundant earlier in life—in the visual cortex of mice can fend off this decline.

Aug 15, 2017
The Scientist Staff

An artificially colored immunofluorescence image depicting labeled Arc protein (green) within the visual cortex of a transgenic mouse engineered to overexpress the Arc gene following exposure to light.ELISSA PASTUZYNArtificially increasing Arc through transgenic overexpression in engineered mice or via viral vectors later in life can prolong and re-establish, respectively, brain plasticity in the visual cortex. 

See K.R. Jenks et al., “Arc restores juvenile plasticity in adult mouse visual cortex,” PNASdoi:10.1073/pnas.1700866114, 2017.

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

Every minute counts when waiting for accurate diagnostic test results to guide critical care decisions, making today's clinical lab more important than ever. In fact, nearly 70 percent of critical care decisions are driven by a diagnostic test.

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN Ltd are pleased to announce the commercial licensing of CRISPR-Cas9 gene-editing technology from Broad Institute of MIT and Harvard in the USA, to develop human cell disease models to support preclinical metabolic disease therapeutic programmes.